“…Terpenes represent one such class of compounds in cannabis that until recently have not been thoroughly investigated for potential therapeutic effects (Russo, 2011). While a growing body of literature suggests that terpenes might offer beneficial effects ranging from antinociception (Peana et al ., 2006; Batista et al ., 2008, 2010; Gertsch et al ., 2008; Berliocchi et al ., 2009; Kuwahata et al ., 2013; Nascimento et al ., 2014; Piccinelli et al ., 2015, 2017; Medeiros Venancio et al ., 2016; Araujo-Filho et al ., 2017; Segat et al ., 2017; Aguilar-Avila et al ., 2019; Aly et al ., 2019; Abbasijahromi et al ., 2020; LaVigne et al ., 2021; Bilbrey et al ., 2022), to anxiolytic properties (Linck et al ., 2010; Souto-Maior et al ., 2011; Bahi et al ., 2014; Harada et al ., 2018; Abbasijahromi et al ., 2020), the pharmacological mechanisms of these purported effects remain poorly characterized (see Russo, 2011 for a summary of the proposed pharmacological effects of terpenes). Two recent reports suggested that CB1 receptors might be one target for a number of terpenes present in cannabis (LaVigne et al ., 2021; Bilbrey et al ., 2022) as evidenced by cannabimimetic activity in the tetrad assay.…”